Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Azitra Inc (AZTR)

Azitra Inc (AZTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules PR Newswire - Mon Nov 24, 8:00AM CST

BRANFORD, Conn. , Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates PR Newswire - Wed Nov 12, 4:15PM CST

BRANFORD, Conn. , Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. Addresses False Report Regarding Sale of Securities PR Newswire - Fri Nov 7, 5:00AM CST

BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris PR Newswire - Mon Oct 20, 7:02AM CDT

ATR-01, which uses a filaggrin-secreting strain of S. epidermidis , is in preclinical development for ichthyosis vulgaris

AZTR : 0.3660 (-1.37%)
Azitra Inc Faces NYSE Compliance Deadline Notice Tipranks - Sat Oct 4, 4:30PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Azitra Inc...

AZTR : 0.3660 (-1.37%)
Azitra Receives Notice of Non-Compliance from NYSE American PR Newswire - Fri Oct 3, 3:45PM CDT

BRANFORD, Conn. , Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire - Thu Sep 4, 7:10AM CDT

BRANFORD, Conn. , Sept. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash PR Newswire - Wed Aug 27, 7:10AM CDT

BRANFORD, Conn. , Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates PR Newswire - Mon Aug 11, 4:00PM CDT

BRANFORD, Conn. , Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...

AZTR : 0.3660 (-1.37%)
Azitra, Inc. Announces Reverse Stock Split PR Newswire - Mon Aug 11, 3:15PM CDT

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025

AZTR : 0.3660 (-1.37%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot